Skip to main content

Industry News

  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, is planning to conduct a new, confirmatory phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency (AGHD), as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarisation.

  • India is examining whether to take up with World Trade Organisation (WTO) the European Union's (EU) suspension order for sale of about 700 generic drugs which were approved based on clinical trials by pharma major GVK Biosciences.

  • Sun Pharmaceutical Industries has inked a pact with Israel's Technion university to develop anti-cancer drugs. The subsidiaries of the Mumbai-based drug firm and Technion - Israel Institute of Technology have entered into an exclusive worldwide research and license agreement, Sun Pharma said in a statement.

Subscribe to Industry News